Description
If you are able to “test and treat” patients for group A streptococcus in your practice, this course is for you! You’ll learn the signs, symptoms, and diagnostic criteria for group A strep; how to evaluate patients for screening eligibility, and how to apply algorithms to treat group A strep in your patients.
Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Identify the regulatory considerations for a pharmacy-led point-of-care service
2. List the signs, symptoms, and diagnostic criteria of group A streptococcus (GAS)
3. Evaluate patients eligible for pharmacy-led POCT screenings
4. Apply treatment and monitoring plans to patients receiving POCT services
5. Formulate evidence-based recommendations for persons with group A streptococcus (GAS)
John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad
John A. Galdo reports he is CEO of Seguridad and his spouse works for Eli Lilly and was an employee of Prime Therapeutics. All relevant financial relationships have been mitigated.
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: October 16, 2024
Planned Expiration Date: October 16, 2025
Copyright 2024, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Reviews
There are no reviews yet.